KBC Securities - Zealand Pharma A/S (ZLDPF) Morning Notes : ZEAL DC

Report

KBC Securities

Hilde Van Boxstael ...

Jacob Mekhael
Thomas Couvreur
Wim Lewi

Morning Notes : ZEAL DC

: ZEAL DC

17/03/2025 1 EN

Underlying

Zealand Pharma A/S

Zealand Pharma is a biotechnology company. Co. is engaged in the discovery development and commercialization of peptide-based medicines. Co.'s pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and obesity treatment, such as Lyxumia (Lixisenatide), Lyxumia/Lantus, ZP2929 and Danegaptide. The Other indications area are ZP1848, Elsiglutide and ZP1480 (ABT-719) drugs for inflammatory bowel disease, chemotherapy-induced diarrhea and acute kidney injury treatment.

See profile

DK0060257814 Pink OTC Markets United States

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Hilde Van Boxstael

Jacob Mekhael

Thomas Couvreur

Wim Lewi

Other Reports on these Companies

KBC Securities

Zealand Pharma Completes petrelintide phase 2b enrolment in obesity/overweight

Zealand announced that the last participant has been enrolled and randomised in the phase 2b (ZUPREME-1) trial of petrelintide (long acting amylin analog, SC) in people with obesity or overweight with weight-related comorbidities. While the company has not provided specific guidance for when results will be released, we expect this to be around 1Q26 taking into account the 42 week treatment period. We reiterate our DKK 970 TP and BUY rating.

15h / 52m 15h / 52m 1 EN

GlobeNewsWire

Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity

Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity Press release – No. 4 / 2025 Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity Initiated in December 2024, the Phase 2b ZUPREME-1 trial is designed to evaluate five target doses of petrelintide up to 9 mg over 42 weeks of treatment.Zealand Pharma remains on track to initiate the Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabet...

16h / 57m 16h / 57m 1 EN

Real Assets Conference Book 19-20 March 2025

We publish our conference book with info on the panels, the graphs on the market and company profiles. European REITS suffered from macro and geo-political worries (logistics) Also, the European knee-jerk reaction on the bund (+60 bps) had a negative effect. We believe that despite these worries, REITS are a good place to hide, given their high visibility and proven growth potential in a tough environment. Our top-picks are Shurgard, WDP and Xior. SHUR and WDP have ample headroom on their balance sheet to continue their growth track record. WDP is also cheap on cash earnings metrics vs. peers....

15h / 34m 15h / 34m 1 EN

Jacob Mekhael

Jacob Mekhael

Zealand Pharma Completes petrelintide phase 2b enrolment in obesity/overweight

15h / 52m 15h / 52m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Morning Notes : ZEAL DC

We are a financial services provider for several types of professional clients, each with distinct needs.

Zealand Pharma Completes petrelintide phase 2b enrolment in obesity/overweight

Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity

Real Assets Conference Book 19-20 March 2025

Zealand Pharma Completes petrelintide phase 2b enrolment in obesity/overweight

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe